EVOKE PHARMA, INC. Proceeds from Issuance Initial Public Offering
EVOKE PHARMA, INC. reported Proceeds from Issuance Initial Public Offering of $6.72 million for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-13.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceInitialPublicOffering · last filed 2024-08-13
- EVOKE PHARMA, INC. proceeds from issuance initial public offering for the quarter ending 2024-06-30 was -$1.00.
- EVOKE PHARMA, INC. proceeds from issuance initial public offering for the quarter ending 2024-03-31 was $6.72M.
- EVOKE PHARMA, INC. proceeds from issuance initial public offering for fiscal 2013 was $28.98M.
| Period end | Proceeds from Issuance Initial Public Offering 0 month | Proceeds from Issuance Initial Public Offering 3 month | Proceeds from Issuance Initial Public Offering 6 month | Proceeds from Issuance Initial Public Offering 12 month |
|---|---|---|---|---|
| 2024-06-30 | -$1.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $6.72M 10-Q · filed 2024-08-13 | ||
| 2024-03-31 | $6.72M 10-Q · filed 2024-05-14 | |||
| 2013-12-31 | $28.98M 10-K · filed 2014-03-25 | |||
| 2013-10-31 | $25.10M 10-K · filed 2015-03-04 |